High pancreatic-specific lipase
VeDDRA Code: 2692
799 adverse event reports referencing this reaction
Species Most Affected
Breeds Most Affected
Associated Drugs
Data Summary
| Metric | Value |
|---|---|
| Total reports referencing reaction | 799 |
| Reports with fatal outcome | 126 |
| Case-fatality rate (reported events) | 1580.0% |
| Species observed | 2 |
| Breeds observed | 20 |
| Drugs associated with reaction | 20 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 2692.
High pancreatic-specific lipase Reaction Insights
The FDA Center for Veterinary Medicine database currently lists 799 adverse event reports that reference High pancreatic-specific lipase as a reaction term, including 126 reports with a death outcome — a 1580.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 2692, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.
High pancreatic-specific lipase appears most frequently in reports for Dog (541 reports), Cat (258 reports) — with Dog dominating at 541 entries. Within those species, the breeds most often named alongside this reaction are Domestic Shorthair (167), Crossbred Canine/dog (51), Retriever - Labrador (37). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.
The drugs most commonly co-reported with High pancreatic-specific lipase are Trilostane (140 reports), Velagliflozin Proline Monohydrate (89 reports), Bexagliflozin (86 reports), Bedinvetmab (85 reports), with Trilostane appearing alongside this reaction in 140 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.